SCHEMBL3687167

SCHEMBL3687167

CCC(C)Oc1ccc(C=CC(=O)O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.58
ATM Q13315 1/20 0.58
HDAC1 Q13547 3/20 0.57
HDAC2 Q92769 3/20 0.57
HDAC8 Q9BY41 3/20 0.57
KDM4E B2RXH2 3/20 0.54
MAPK1 P28482 1/20 0.54
LTB4R Q15722 1/20 0.50
LTB4R2 Q9NPC1 1/20 0.50
TAS1R3 Q7RTX0 2/20 0.48
TAS1R1 Q7RTX1 2/20 0.48
HCAR2 Q8TDS4 2/20 0.47
ESR1 P03372 2/20 0.47
ESR2 Q92731 2/20 0.47
CA12 O43570 1/20 0.47
AKR1B10 O60218 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA3 P07451 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3687164 1.00 THRB (0.58) THRBATMHDAC1HDAC2HDAC8
SCHEMBL8072187 0.88 THRB (0.55) THRBATMHDAC1HDAC2HDAC8
SCHEMBL8072186 0.88 THRB (0.55) THRBATMHDAC1HDAC2HDAC8
SCHEMBL8072207 0.85 THRB (0.53) THRBATMHDAC1HDAC2HDAC8
SCHEMBL8072206 0.85 THRB (0.53) THRBATMHDAC1HDAC2HDAC8
SCHEMBL8084861 0.85 THRB (0.55) THRBATMKDM4EMAPK1LTB4R
SCHEMBL19244210 0.85 HDAC1 (0.52) HDAC1HDAC2HDAC8KDM4ELTB4R
SCHEMBL19244461 0.85 CA12 (0.55) HDAC1HDAC2HDAC8KDM4ETAS1R3
SCHEMBL19244211 0.85 HDAC1 (0.52) HDAC1HDAC2HDAC8KDM4ELTB4R
SCHEMBL19244462 0.85 CA12 (0.55) HDAC1HDAC2HDAC8KDM4ETAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795310-B2 Methods and reagents for the treatment of metabolic disorders COMBINATORX, INC. (US) 2010-09-14 US disclosed
US-20060069161-A1 Methods and reagents for the treatment of metabolic disorders COMBINATORX, INC. (US) 2006-03-30 US disclosed
EP-0758013-B1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL CO LTD (JP) 2000-10-11 EP disclosed
US-5855971-A Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film NIPPON OIL COMPANY, LIMITED (JP) 1999-01-05 US disclosed
EP-0758013-A1 Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display NIPPON OIL COMPANY, LIMITED (JP) 1997-02-12 EP disclosed
US-4026896-A ANTIALLERGENS KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) 1977-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069161-A1 Methods and reagents for the treatment of metabolic disorders LIPC, PNLIP, GOT2 THRB 949/4885ATM 1620/4885HDAC1 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.